Alfacalcidol
- Generic Name
- Alfacalcidol
- Brand Names
- One-alpha
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O2
- CAS Number
- 41294-56-8
- Unique Ingredient Identifier
- URQ2517572
- Background
Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D. It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacologi...
- Indication
Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.
...
- Associated Conditions
- Hypocalcemia, Hypophosphatemic Rickets, Nutritional Rickets, Osteodystrophy, Osteomalacia, Rickets, Secondary Hyperparathyroidism (SHPT), Hypophosphatemic osteomalacia
- Associated Therapies
- -
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT00469599
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Århus University Hospital Skejby, Aarhus, Denmark
🇩🇰Hospital of Southwest Denmark Esbjerg, Esbjerg, Denmark
Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 282
- Registration Number
- NCT00168909
- Locations
- 🇩🇪
Centre for Muscle and Bone Research, Aerpah-Kliniken Esslingen, Stuttgart, Germany
🇩🇪Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin, Berlin, Germany
Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT00165698
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Hua Dong Hospital, Shanghai, China
🇨🇳Chinese PLA General Hospital, Beijing, China
A New Active Vitamin D, ED-71 for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 1056
- Registration Number
- NCT00144456
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.